Business

Eris Lifesciences Acquires 30% Stake in Swiss Parenterals in Strategic Rs 423 Crore Deal

With this investment, Eris cements its position in a market segment that demands high regulatory standards, manufacturing capabilities and global supply-chain agility.

• By Newsdesk
• New Delhi
• Nov 24, 2025

Business

Indian pharmaceuticals company Eris Lifesciences has taken a decisive step to strengthen its presence in sterile injectables, acquiring a 30 percent stake in Swiss Parenterals Ltd for approximately Rs 423 crore. 

The move builds on an earlier transaction in which Eris secured majority ownership of the company, and now consolidates its strategy to capture growth in the rapidly evolving injectables segment. With this investment, Eris cements its position in a market segment that demands high regulatory standards, manufacturing capabilities and global supply-chain agility.

Swiss Parenterals is a specialist in sterile injectable manufacturing and has an established presence in emerging markets, giving Eris immediate access to export-oriented operations and sophisticated production infrastructure. This aligns with Eris’s stated ambition to grow beyond its branded domestic formulations business and deepen its foothold in complex dosage forms.

For Eris Lifesciences, the takeover of the remaining minority stake is expected to enhance operational control, unlock synergies and accelerate scale-up of its injectables platform. Industry analysts suggest that this tranche of investment positions the company to harness rising demand for sterile injectable therapies and enter adjacent segments of critical care, hospital-based medicines and emerging markets.

The deal is also significant from a financial-strategy perspective. By taking on the stake at this juncture, Eris not only reinforces its manufacturing backbone but also pre-emptively responds to shifts in pharmaceutical supply-chains and regulatory dynamics where local manufacturing of advanced dosage forms is increasingly becoming a competitive advantage.

In the coming months, all eyes will be on how Eris integrates Swiss Parenterals’ operations, leverages its global footprint and taps the value creation potential inherent in high-barrier injectable segments. For shareholders, the transaction underscores Eris’s transition from a branded-formulations player to one with growing credentials in specialised manufacturing and exports.

(Source: Zee Business)